Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia.

Background: Targeted therapies exploiting vulnerabilities of cancer cells hold promise for improving patient outcome and reducing side-effects of chemotherapy. However, efficacy of precision therapies is limited in part because of tumor cell heterogeneity. A better mechanistic understanding of how drug effect is linked to cancer cell state diversity is crucial for identifying effective combination therapies that can prevent disease recurrence.

Transcription Factors of the GLRs Family Are Involved in Cytokinin-Dependent Regulation of Plastid RNA Polymerase SCA3 Gene Expression during Deetiolation of Arabidopsis thaliana.

Light-dependent transcription factors GLKs of Arabidopsis thaliana are involved in the anterograde regulation of chloroplast biogenesis during deetiolation: they regulate the expression of photosynthetic nuclear-encoded genes and also mediate the transcription of plastid genes. Chloroplast biogenesis is determined at the same time by light and by endogenous factors (phytohormones), among which cytokinins significantly accelerate the formation of photosynthetically active chloroplasts. In this work, it was shown that trans-factors GLKs function as cytokinin-dependent regulators, mediating the positive cytokinin effect on the plastome expression through the activation of transcription of the SCA3 nuclear gene encoding the plastid RNA polymerase RPOTp.

IFNγ directly counteracts imatinib-induced apoptosis of primary human CD34+ CML stem/progenitor cells potentially through the upregulation of multiple key survival factors.

Tyrosine kinase inhibitors (TKIs) have dramatically improved the survival in chronic myeloid leukemia (CML), but residual disease typically persists even after prolonged treatment. Several lines of evidence suggest that TKIs administered to CML patients upregulate interferon γ (IFNγ) production, which may counteract the anti-tumorigenic effects of the therapy. We now show that activated T cell-conditioned medium (TCM) enhanced proliferation and counteracted imatinib-induced apoptosis of CML cells, and addition of a neutralizing anti-IFNγ antibody at least partially inhibited the anti-apoptotic effect.

Combination of tyrosine kinase inhibitors and the MCL1 inhibitor S63845 exerts synergistic antitumorigenic effects on CML cells.

Tyrosine kinase inhibitor (TKI) treatment has dramatically improved the survival of chronic myeloid leukemia (CML) patients, but measurable residual disease typically persists. To more effectively eradicate leukemia cells, simultaneous targeting of BCR-ABL1 and additional CML-related survival proteins has been proposed. Notably, several highly specific myeloid cell leukemia 1 (MCL1) inhibitors have recently entered clinical trials for various hematologic malignancies, although not for CML, reflecting the insensitivity of CML cell lines to single MCL1 inhibition.